Osvyrti (Denosumab-Desu)
Brand Names: Osvyrti
Methodology & AI Transparency ⓘ
Osvyrti (Denosumab-Desu) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within the RANK Ligand Inhibitor category, Osvyrti provides branded delivery of active pharmaceutical ingredient Denosumab-Desu (registered by Accord BioPharma Inc.; NDC 69448-021).
- 2 Real-world patient consensus: Registered under RxNorm 2746871 and SPL 2026-07-07, pairing Osvyrti packaging with active ingredient Denosumab-Desu.
- 3 Typical cash cost range: 30-day cash pricing ranges from $103.54 discount cash to $274.38 walk-in retail (NADAC $1.3200/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Osvyrti (Denosumab-Desu)): nausea (8.2%), headache (8%), dizziness (6.6%).
Ask our AI Specialists anything about Osvyrti (Denosumab-Desu)
Osvyrti (Denosumab-Desu) Mechanism, CYP450 Pathways & DailyMed Monograph
Within the RANK Ligand Inhibitor category, Osvyrti provides branded delivery of active pharmaceutical ingredient Denosumab-Desu (registered by Accord BioPharma Inc.; NDC 69448-021). Characterized by 60 mg/mL Injection; Longitudinal Osvyrti (Denosumab-Desu) dosing interval tailored to tolerability under 2026-07-07 SPL documentation, Osvyrti targets 1 Indications and usage osvyrti: is a RANK ligand (RANKL) inhibitor indicated for: of postmenopausal women with.
Through its Denosumab-Desu active moiety, Osvyrti exerts rank ligand inhibitor activity with class-characteristic hepatorenal disposition. Registered under NDC 69448-021 (registered by Accord BioPharma Inc.; effective 2026-07-07), the 60 mg/mL Injection; Longitudinal Osvyrti (Denosumab-Desu) dosing interval tailored to tolerability presentation ensures reproducible pharmacokinetic release profiles documented in federal RxNorm (2746871) and CMS NADAC ($1.3200/unit) ledgers.
With Terminal t½ estimated at 7–19 hrs depending on renal/hepatic reserve (Osvyrti (Denosumab-Desu)) residence kinetics and Complete (~100%) parenteral systemic delivery for Osvyrti (Denosumab-Desu) (60 mg/mL Injection) bioavailability, Osvyrti (Denosumab-Desu) undergoes mixed metabolic conjugation and unchanged urinary excretion across osvyrti (denosumab-desu) regimens and establishes therapeutic activity over rapid intravascular/parenteral onset within 15–45 minutes after osvyrti (denosumab-desu) administration.
Standard adult regimens span 60 mg/mL Injection, Longitudinal Osvyrti (Denosumab-Desu) dosing interval tailored to tolerability. Prescribers screen specifically against severe drug-induced hypersensitivity to denosumab-desu or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-07-07 for osvyrti (denosumab-desu), while community micro-logs most frequently note nausea (8.2% of reports), headache (8% of reports), dizziness (6.6% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Osvyrti (Denosumab-Desu) (rank ligand inhibitor).
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Osvyrti (Denosumab-Desu) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Denosumab-Desu or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-07-07 for Osvyrti (Denosumab-Desu)
Logged Side-Effect Incidence (16 Reports)
Osvyrti (Denosumab-Desu) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Osvyrti (Denosumab-Desu))
Human clinical trial evidence for Osvyrti (Denosumab-Desu) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Osvyrti (Denosumab-Desu) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.3200/unit (~$39.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $274.38 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $103.54 / mo | View logs ↓ |
Osvyrti (Denosumab-Desu) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Osvyrti (Denosumab-Desu) RxNorm Concept ID | 2746871 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.3200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $274.38 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $103.54 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Osvyrti (Denosumab-Desu) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Osvyrti (Denosumab-Desu): FDA labeling (2026-07-07, NDC 69448-021), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Osvyrti (Denosumab-Desu) community threads and patient logs by age, biological sex, dosage, and treatment duration.